-
At issue in the case is more than abortion rights. It's the entire structure of the FDA's regulatory power to approve drugs and continually evaluate their safety.
-
These cases raise a critical question for the First Amendment and the future of social media: whether states can force the platforms to carry content they find hateful or objectionable.
-
Idaho's "Defense of Life Act" would would make it a crime for "every person who performs or attempts to perform an abortion," even when the woman's health is greatly endangered.
-
The court's action sets up a collision between the Food and Drug Administration's 23-year study and supervision of mifepristone, and the circumstances under which it can be prescribed.
-
The court turned away an appeal from Washington, where the law has been upheld. An appellate panel had struck down local bans in Florida, and the high court often steps in when appellate courts disagree.
-
The law that allows the state to revoke the licenses of therapists who try to change a minor's sexual orientation. Since the 2018 ruling, the 11th U.S. Circuit Court of Appeals in Atlanta has voided the local Florida bans.
-
The justices struggled to decide whether to give a thumbs up or thumbs down to the multibillion dollar Purdue Pharma bankruptcy deal -- a deal meant to compensate victims of OxyContin.
-
Should the nation’s highest court agree to take the case, it would mark the first time the justices will weigh in on the debate surrounding restrictions on puberty blockers and hormone therapy for minors.
-
Supreme Court's decision to review the controversial bankruptcy deal involving the maker of Oxycontin means the settlement will remain on hold at least through December.
-
Some medical professionals are concerned the decision could have implications for the diversity of medical students, the practice of medicine, and patient care.